Table 4.
Proportional hazard regression model for OS and DSS of MIBC patients by treatment time and treatment modality.
| Time by modality | No. of patients | Overall survival (OS) | Disease-specific survival (DSS) | |||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| 1 year | RC-MIBC cohort | 891 | 1.00 [reference] | 1.00 [reference] | ||
| TMT-MIBC cohort | 891 | 1.07 | 0.84-1.36 | 1.11 | 0.89-1.44 | |
| 5 years | RC-MIBC cohort | 891 | 1.00 [reference] | 1.00 [reference] | ||
| TMT-MIBC cohort | 891 | 1.26 | 1.01-1.53 | 1.30 | 1.04-1.59 | |
| 10 years | RC-MIBC cohort | 891 | 1.00 [reference] | 1.00 [reference] | ||
| TMT-MIBC cohort | 891 | 0.92 | 0.71-1.26 | 0.99 | 0.80-1.35 | |
Analyses were based on the Cox PH regression. All baseline covariates were well balanced in the propensity score-matched sample according to demographic and clinicopathological characteristics. Therefore, only treatment information was controlled for in the final Cox PH regression model. OS: overall survival; DSS: disease-specific survival; HR: hazard ratio; CI: confidence interval; RC: radical cystectomy; TMT: bladder-sparing trimodality therapy; MIBC: muscle-invasive bladder cancer.